Navigation Links
Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Date:8/31/2009

NEW YORK, Aug. 31 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will present an overview of the Company's lead drug candidates, KRX-0401 (perifosine) and Zerenex(TM), at the upcoming Rodman & Renshaw Annual Global Investment Conference in New York City. Mr. Bentsur's presentation will take place on Wednesday, September 9th at 2:50 pm ET at the New York Palace Hotel (Spellman Salon, 5th Floor) and will be audio webcast live, accessible from the Investor Information page of the Company's website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

Additionally, Keryx Biopharmaceuticals, Inc. today announced that it will host an Investor/Analyst Day on Tuesday, September 22nd in New York City beginning at 5:30 pm ET, by invitation only. Scheduled speakers include:

Discussing Perifosine Phase 3 SPA in Multiple Myeloma:

Kenneth C. Anderson, M.D.

  • Director, Jerome Lipper Multiple Myeloma Center and Chief, Division of Hematologic Neoplasia, Dana-Farber Cancer Institute.
  • Dr. Anderson's team at Dana-Farber Cancer Institute led clinical trials in multiple myeloma of the novel proteasome inhibitor Velcade(R), as well as the immunomodulatory drug Revlimid(R).

Discussing Perifosine Phase 2 Results in Colon Cancer:

Johanna Bendell, M.D.

  • Director, GI Oncology Research and Assoc. Director, Drug Development Unit, Sarah Cannon Research Institute.
  • Dr. Bendell has served as an investigator in numerous colorectal trials including capecitabine, oxaliplatin and bevacizumab (XELOX + AVASTIN(R)).

Discussing Zerenex Planned Phase 3 Program in Hyperphosphatemia:

Julia Lewis, M.D.

  • Professor of Medicine, Division of Nephrology, Vanderbilt University School of Medicine.
  • Dr. Lewis has participated in the design and execution of the IDNT Trial, the AASK Trial, the Cohort Study, and HEMO Study, as well as other important clinical trials.

The Investor/Analyst Day presentations will be audio webcast live, accessible from the Investor Information page of the Company's website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including renal disease and cancer. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: There can be no assurance that the Company will complete cost-effective clinical trials or meet the projected development timelines for the drug candidates in its pipeline, including KRX-0401 and Zerenex; that the Company will be able to raise additional capital in the future in order to fund its operations; or that the Company's stock will not be affected by other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.

    KERYX CONTACT:
    Lauren Fischer
    Director - Investor Relations
    Keryx Biopharmaceuticals, Inc.
    Tel: 212.531.5965
    E-mail: lfischer@keryx.com


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Keryx Biopharmaceuticals Settles License Dispute With Alfa Wassermann
2. Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX-0401 (Perifosine) in the Treatment of Multiple Myeloma
3. Keryx Biopharmaceuticals Inc. Regains Compliance With NASDAQ Listing Requirements
4. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance
5. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
6. Keryx Biopharmaceuticals, Inc. Requests an Appeal Hearing After Receiving Notice of Delisting From Nasdaq
7. Keryx Biopharmaceuticals Receives Nasdaq Notification
8. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2008 Financial Results
9. Keryx Biopharmaceuticals KRX-0401 (Perifosine) Data Selected for Oral Presentation at the 50th Annual Meeting of the American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2008 Financial Results on Tuesday, November 11, at 8:30 A.M. EST
11. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... 2016 , ... Basketball is a game for everyone, not just those who ... sign language translation is featured in the top right of the screen. Every technique ... has a sign language translator to teach kids the game and how to be ...
(Date:2/11/2016)... ORLEANS (PRWEB) , ... February 11, 2016 , ... “ ... Achieving Satisfaction through a Well Managed Mind” (published by Balboa Press) teaches readers how ... way of being through profound love, author Janice McDermott, M.Ed., LCSW, offers an understanding ...
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. Sadati’s recent feature in ... Along with performing procedures, the magazine also highlights that Dr. Sadati has pioneered ... of the most common procedures he performs is his natural facelift. “As people ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... ... the healthcare industry, ranked among the top five firms in the “2015/2016 Best ... HIT Implementation Support and Staffing. KLAS is a research and insights firm on ...
(Date:2/11/2016)... ... February 11, 2016 , ... Atlantic Information Services, Inc. ... Model: A Case Study for Plans and Purchasers.” Executives from Intel Corp. and ... Intel on value-based health benefits program Connected Care, will discuss the challenges they ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 11, 2016 - Cardiac ... Personalized Medicine and Cancer Therapy. - European Point ... Testing Markets. - Key Diagnostic Testing Markets. ... Diagnostics in Genetic Testing. - Molecular Diagnostics in ... - Over-the-Counter Diagnostic Products World Markets. - Point ...
(Date:2/11/2016)... -- Kindred Biosciences, Inc. (NASDAQ: KIN ), a biopharmaceutical ... pets, today announced the submission to FDA of the ... (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive topline results ... the control of pyrexia (fever) in horses were recently ... --> The Chemistry, Manufacturing, and Controls technical ...
(Date:2/11/2016)... 2016  NOIT™ Research LLC, a private, leading-edge autism ... campaign to assist needy families in obtaining one of ... between February 10, 2016 and March 31, 2016, the ... The NOIT is an auditory stimulus that plays a ... skills. Beth Shier , NOIT Research ...
Breaking Medicine Technology: